{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-018231","form_type":"8-K","ticker":"AIXC","cik":"0001460702","company_name":"AIxCrypto Holdings, Inc.","filed_at":"2023-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.933613+00:00","generated_at":"2026-06-14T19:40:04.133791+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Qualigen Therapeutics President, COO and Director Amy Broidrick to resign effective June 16, 2023","bullets":["Amy Broidrick, President, Chief Strategy and Operating Officer, and director, submitted resignation effective June 16, 2023.","Her departure is not related to any disagreement with the company on operations, policies, or practices.","She will resign from all officer and director positions with the company and its subsidiaries.","Company intends to enter into a separation agreement and general release with Ms. Broidrick."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-018231","json":"https://secwatch.observer/filing/0001493152-23-018231.json","markdown":"https://secwatch.observer/filing/0001493152-23-018231.md","text":"https://secwatch.observer/filing/0001493152-23-018231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1460702/000149315223018231/0001493152-23-018231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1460702/000149315223018231/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T19:40:04.133791+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4025de5426","claim":"Amy Broidrick resigned as President, Chief Strategy and Operating Officer and Director at AIxCrypto Holdings, Inc..","evidence_excerpt":"On May 16, 2023, Amy Broidrick, President, Chief Strategy and Operating Officer and a director of Qualigen Therapeutics, Inc. (the “Company”), provided her resignation to the Company, which will become effective June 16, 2023 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1460702/000149315223018231/0001493152-23-018231-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President, Chief Strategy and Operating Officer and Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}